B+
Bull case
25%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
FTH
Faeth TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Faeth has a substantial post-financing cash position and two PIKTOR clinical programs, with the key Phase 2 endometrial-cancer readout expected by year-end 2026 and a second indication entering clinical development. [#SEC-8K-2026-08-04]
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -7.9.
What can break
Binary efficacy and safety risk around the PIK-201 Phase 2 topline readout.
Momentum
98
Value
41
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $26.00 · Bull $48.00 · Bear $14.00Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $55.10
Why
Momentum98 · Δ7d +4.5
Value41 · Δ7d 0.0
Sentiment38 · Δ7d -7.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -7.9.
Contradictions & invalidation
- • Binary efficacy and safety risk around the PIK-201 Phase 2 topline readout.
- • Future financing and capital-structure risk remain relevant despite the reported post-PIPE cash balance.
- • The thesis remains binary and data-light: no efficacy readout is available, PIK-201 could disappoint, PIK-101 is early-stage, and Q2 R&D and G&A expenses rose to $9.2 million each.
Catalyst clock
2026-08-04
Q2 results reaffirm funded clinical timeline
Lead driver: Sentiment · See AI snapshot
Momentum
98
9% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
-0.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
38
62% active weight
Current posture
7d trendSoftening
Δ7d
-7.9
Δ21d
-15.3
Why this grade
Composite grade D. Momentum 97.5 / Value 41.2 / Sentiment 37.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$846.79M
Beta
0.28
Shares Out
25.84M
P/E (TTM) · Derived
-2.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.93
Rev YoY
-
EPS YoY
-27.5%
Gross Margin
-
Op Margin
-
Net Debt
-$19.68M
Current Ratio
19.69
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data